Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the results of its Annual General Meeting held on June 20, 2025. Key resolutions approved include the financial budget for 2025, re-appointment of KPMG as auditors, and the election of new non-executive directors. Amendments to the Articles of Association and the abolishment of the Supervisory Committee were also approved, indicating a strategic shift in the company’s governance structure. These changes are expected to streamline operations and potentially enhance the company’s market position.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and production of biopharmaceutical products. The company is involved in the research and development of innovative drugs and therapies, catering primarily to the healthcare industry.
Average Trading Volume: 906,033
Technical Sentiment Signal: Buy
Current Market Cap: HK$79.89B
Find detailed analytics on 6990 stock on TipRanks’ Stock Analysis page.